NCT02674321View on ClinicalTrials.gov

A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
TOURETTE SYNDROME
Interventions
DRUG

SD-809

Trial Locations (1)

77030

Teva Investigational Site #101, Houston

Sponsors
All Listed Sponsors
lead

Auspex Pharmaceuticals, Inc.

INDUSTRY

NCT02674321 - A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS) | Biotech Hunter | Biotech Hunter